[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"muscle-atrophy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:muscle-atrophy":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,56,80,106,135,158,185,214,239,267,286,308,339,365,391],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100590209","postoperative-electrical-muscle-stimulation-two-100590209",false,"NCT06964438","Postoperative Electrical Muscle Stimulation Two","A Three-Arm Randomised Controlled Trial to Establish Effectiveness of NMES With or Without Protein Supplementation to Preserve Muscle Mass and Strength and Improve Functional Outcomes After Abdominal Surgery for GI Cancer","POEMS2","Inclusion Criteria:\n\n* Adult patients (age 18 or over at the time of diagnosis made at MDT (multi-disciplinary team meeting)\n* MDT outcome of colorectal or gastric cancer or non-invasive neoplasia (tissue-proven, or radiologically diagnosed and clinically suspected) with the intention to treat with curative abdominal surgery\n* Agreed management plan for open or minimally invasive (laparoscopic or robot assisted) segmental abdominal (colonic or gastric) resection at the Royal Derby Hospital\n* Sufficient mobility and fitness to complete normal ERAS (enhanced recovery after surgery) protocols following surgery\n* Basic conversational spoken English language\n* Ability to give informed consent\n\nExclusion Criteria:\n\n* Upper GI (gastrointestinal) cancer requiring thoracotomy\u002Fthoracoscopy\n* Pre-existing neuromuscular disease (including Parkinsons disease)\n* Pacemaker, implantable cardiac defibrillator or other implanted nerve stimulator device\n* Metal prostheses or other metal-work in either upper legs (hip\u002Fknee\u002Ffemur)\n* Dementia or other cognitive problem or language barrier causing an inability to follow instructions and operate NMES machine\n* Inability to give informed consent\n* Disability preventing completion of ERAS after surgery (requiring Zimmer frame\u002Fwheeled frame\u002Fwheelchair to mobilise or bed-bound)\n* Peripheral vascular disease\n* Epilepsy\n* Pre-existing diagnosis of chronic kidney disease or estimated glomerular filtration rate \\\u003C60 on screening visit\n* Pre-existing diagnosis of liver disease\n* Intubation or intensive care admission during study period (between day 0-5 post-op); (surgical high dependency unit patients will be included)\n* Return to theatre for surgical complication within first 5-days post operation\n* History of rhabdomyolysis\n* Pregnancy\n* Deep vein thrombosis within past 6-months\n* Allergy to whey protein\n* Patient refusal of whey protein products on grounds of dietary requirements or intolerance\n* Participating in another clinical trial concurrently or within the last 6 months\n* Known infection with blood borne virus","ALL","18 Years",{"count":20,"type":21},45,"ESTIMATED","INTERVENTIONAL",[24],"NA","Undesirable loss of skeletal muscle mass (atrophy) is a common feature of many diseases as well as ageing, bed rest and physical inactivity. Losing muscle can lead to a reduction in one's ability to perform physical activities, and reduce independence and overall health. Muscle mass loss occurs very quickly (i.e., within a few days) after surgery.\n\nThe investigators previous work has shown that neuromuscular electrical stimulation (NMES) of the thigh muscles on one side of the body can help maintain muscle mass and strength on the stimulated side after surgery. Since then, additional work has been carried out to find the most effective form of stimulation to build muscle.\n\nThe current study aims to use this refined stimulation protocol in a clinical trial on the wards after major abdominal surgery. The intervention will involve delivering stimulation to both thighs in the few days after surgery, so that the investigators can assess whether this stimulation can preserve muscle mass and strength, and also, patients' ability to perform physical activities after surgery. In addition, the study will aim to find out whether any benefit provided by electrical stimulation can be increased further by taking a protein supplement at the same time.",[27,28,29,30],"Surgery","Colorectal Cancer","Muscle Atrophy","Cancer Gi",[32,33,34,35,36,37,38,39,40,41,42],"electrical stimulation","neuromuscular electrical stimulation","NMES","rehabilitation","general surgery","colorectal surgery","laparotomy","laparoscopy","postoperative recovery","gastrointestinal cancer","gastrointestinal surgery","RECRUITING","2026-06-10",{"date":46,"type":47},"2026-06-15","ACTUAL",{"date":49,"type":47},"2025-06-05",{"date":51,"type":21},"2027-03-01",{"name":53,"class":54},"University of Nottingham","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":65,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":55},"100301209","impact-of-nmes-and-hpro-on-recovery-after-sah--pilot-study-100301209","NCT03201094","Impact of NMES and HPRO on Recovery After SAH- Pilot Study","Impact of Neuromuscular Stimulation and High Protein Nutritional Supplementation on Long-term Recovery After Aneurysmal Subarachnoid Hemorrhage.","Inclusion criteria:\n\n1. . Being diagnosed with aneurysmal SAH\n2. . Aneurysmal repair within 48 hours of ictus.\n3. . Age between 25 and 80 years old. (\\>=25 years old and \\\u003C=80 years old)\n4. . Expected stay in the NCCU \\> 72 hours.\n5. . Admission Hunt Hess Grade \\>=2.\n6. modified Fisher score \\>1.\n\nExclusion criteria:\n\n1. . Subjects diagnosed with SAH from trauma, rupture of an arteriovenous malformation, neoplasm, vasculitis, or other secondary causes;\n2. . Unlikely to survive one week post hemorrhage either due to impending brain death or likely request for withdrawal of care;\n3. . Unlikely to remain in the ICU for more than 7 days;\n4. . Body mass index \\\u003C 15 or \\>40 kg\u002Fm2;\n5. . Allergy to whey protein;\n6. . Evidence of lower extremity paresis or spasticity within 48 hours of injury\n7. . Pre-morbid modified Rankin Score \\>1.\n8. . Known pregnancy\n9. . Presence of active malignancy\n10. . Diagnosis of an inflammatory disorder\n11. . Presence of a neuromuscular disorder\n12. . Diagnosis of chronic renal insufficiency or acute kidney injury (GFR \\\u003C 30 mL\u002Fmin\u002F1.73m2)\n13. . Hepatic insufficiency defined as AST\u002FALT levels \\>2.5 above normal upper limits.\n14. . On-going seizure activity as assessed clinically or by electrographic detection on continuous electroencephalogram (cEEG) at time of enrollment\n15. . Prisoner.",{"count":64,"type":21},30,[24],"The study purpose is to investigate the hypothesis that in adults with SAH, early neuromuscular electrical stimulation (NMES) and high protein supplementation (HPRO) will improve muscle mass, metabolic and inflammatory biomarker profiles, compared to SAH controls receiving standard of care interventions for nutrition and mobilization. The investigators will accomplish this by studying the effects of a high protein (HPRO) nutritional treatment as well as NMES intervention have upon muscle wasting and motor strength acutely after SAH. This will be addressed in a prospective trial of SAH patients receiving HRPO with NMES as compared to age and severity-matched SAH patients undergoing standard of care interventions for nutrition and mobilization. Additionally, the study will investigate the impact HPRO and NMES interventions have upon inflammatory cytokines and markers of energy balance. Results of this study will establish evidence for precision nutrition plus early exercise to mitigate the catabolic and inflammatory state produced by SAH to improve muscle, metabolic, and health recovery outcomes.",[68,29,69,70],"Subarachnoid Hemorrhage","Inflammation","Nutritional and Metabolic Disease","2026-05-15",{"date":73,"type":47},"2026-05-19",{"date":75,"type":47},"2017-12-01",{"date":77,"type":21},"2026-10-30",{"name":79,"class":54},"University of Maryland, Baltimore",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100519985","phase-2-essential-amino-acid-supplementation-for-femoral-fragility-fractures-100519985","NCT06050668","Essential Amino Acid Supplementation for Femoral Fragility Fractures","MEND Repair & Recover Clinical Trial","Inclusion Criteria:\n\n* Hospital inpatient\n* Age ≥ 65 years old on admission\n* Low-energy mechanism of injury\n* Diagnosis of femur fracture (OTA 31, 32, or 33 fracture)\n* Indicated for surgical fixation\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Part of a vulnerable population (ex: Incarcerated, Non-English speaking)\n* Cognitive impairment (MMSE score ≤ 17)\n* Electrical medical implant (ex: Pacemaker\u002FDefibrillator, Left Ventricular Assist Device, Cochlear implant, Insulin pump, Pain medication pumps, Spinal cord stimulator)\n* Non-ambulatory prior to injury\n* Inability to consume an oral diet or allergy to supplement ingredients (ex: milk allergy)\n* Concern for inability to complete follow-up\n* Hemi or total arthroplasty (joint replacement)\n* Patients with a historical diagnosis of chronic kidney disease (CKD)","65 Years",{"count":89,"type":21},60,[91],"PHASE2","This trial will evaluate the impact of 4 weeks of postoperative essential amino acid (EAA)-based supplementation on muscle morphology after femoral fragility fracture. This trial will assess the ability of EAA-based to increase skeletal muscle metabolic activity, reduce inflammation, and induce muscle fiber hypertrophy, as well as preserve skeletal muscle mass and physical performance up to 6 months after injury. Participants will be randomized in a 1:1 ratio to 1) standard of care (no dietary intervention) or 2) EAA-based supplementation.",[94,95,29],"Femoral Fracture","Fragility Fracture","2026-04-14",{"date":98,"type":47},"2026-04-15",{"date":100,"type":47},"2024-06-17",{"date":102,"type":21},"2026-12",{"name":104,"class":54},"Michael C Willey",2,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":116,"conditions":117,"keywords":123,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100509938","improved-muscle-metabolism-by-combination-of-muscle-activation-and-protein-substitution--imempro--100509938","NCT05919940","Improved Muscle Metabolism by Combination of Muscle Activation and Protein Substitution ( IMEMPRO )","Improved Muscle Metabolism by Combination of Muscle Activation and Protein Substitution: a Randomized, Outcome-assessor Blinded, Proof-of-concept Study (IMEMPRO)","Inclusion Criteria:\n\n* critically ill adults (≥ 18 years of age)\n* newly admitted to the ICU (\\\u003C48h)\n* mechanically ventilated, expected to remain for at least 72h\n* enteral nutrition is feasible\n\nExclusion Criteria:\n\n* a BMI \\> 30\n* expected death or withdrawal of life-sustaining treatments\n* prior neuromuscular disease (e.g. paresis, myopathies, neuropathies)\n* injury or disease preventing neuromuscular electrical stimulation or early mobilization (e.g., elevated intracranial pressure, unstable spine)\n* a pacemaker or other electronic implant\n* allergy to components of NMES adhesive\n* have been dependent during activities of daily living prior to the hospital admission\n* a language barrier",{"count":114,"type":21},40,[24],"Intensive Care Unit Acquired Weakness (ICUAW) describes muscle weakness that occurs in around 40% of patients during an intensive care stay. The morbidity and mortality of these patients is significantly increased over a 5-year period. The aim of this study is to investigate the combined effect of early enteral high-protein nutrition and early muscle activation on muscle atrophy in critically ill patients.\n\nThe study will include 40 patients (20 intervention, 20 observation) with requirement for enteral nutrition at time of inclusion. In the intervention group the maximum possible level of mobilization is carried out and muscles are activated twice a day using neuromuscular electrical stimulation (NMES). The nutrition plan of the intervention group is based on the applicable guidelines for intensive care medicine with exception of increased protein intake. The control group receives therapy without deviating from the standard according of the DGEM guideline.\n\nThe study aims to show that the decrease in muscle mass is significantly less than in the control group (primary hypothesis) via ultrasound of the rectus femoris muscle and in case of given consent muscle biopsy. As secondary hypothesis it is examined whether the combination of early high protein intake and muscle activation improves muscle strength and endurance.",[118,29,119,120,121,122],"ICU Acquired Weakness","Energy Malnutrition Protein","Quality of Life","Morphological and Microscopic Findings","Metabolic Disturbance",[124],"Early Mobilization and high-protein nutrition","2026-02-28",{"date":127,"type":47},"2026-03-03",{"date":129,"type":47},"2023-06-27",{"date":131,"type":21},"2027-01-31",{"name":133,"class":54},"Technical University of Munich",4,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":105},"100487465","a-skeletal-muscle-recovery-intervention-with-dietary-protein-in-heart-failure-100487465","NCT05627440","A SkeleTal Muscle Recovery Intervention With Dietary Protein in Heart Failure","ASTRID-HF","Inclusion Criteria:\n\n1. Left ventricular ejection fraction (LVEF) ≤40%, New York Heart Association (NHYA) class II to IV symptoms or N-terminal pro B-natriuretic peptide (NT-proBNP) \\>300 pg\u002FmL\n2. Age 18 years to 100 years, inclusive\n3. Receiving guideline-directed medical therapy (GDMT), unless contraindicated or not tolerated\n4. Any of the following markers of severe HF within prior 12 months: i) Inotropic therapy; ii) 1 or more HF hospitalizations; iii) LVEF ≤25%; iv) Peak oxygen consumption (VO2) \\\u003C50% predicted or ≤16 mL\u002Fkg\u002Fmin; v) 6-minute walk distance \\\u003C300 meters; vi) Unintentional weight loss \\>5% of bodyweight over the past year; vii) Moderate or severe muscle wasting on physical examination; viii) NT-proBNP ≥900 pg\u002FmL\n\nExclusion Criteria:\n\n1. Pregnancy, planning to become pregnant, or women of reproductive potential unwilling to complete pre-DXA urine pregnancy test before first DXA or randomization\n2. History of left ventricular assist device (LVAD), heart transplantation, or estimated glomerular filtration rate (eGFR) \\\u003C20 mL\u002Fmin\u002F1.73 m2\n3. An identified clinical disorder associated with skeletal muscle weakness\u002Fwasting (e.g., muscular dystrophy, mitochondrial disorder, active cancer, modified Rankin score greater or equal to 4 post-stroke)\n4. Milk allergy, protein allergy, lactose intolerance, and galactosemia\n5. Weight ≥350 pounds and\u002For BMI ≥40 kg\u002Fm2\n6. Initiation of obesity-dosed GLP-1 or GIP\u002FGLP-1 agonist within 3 months prior to screening, or clinical intention to begin such an anti-obesity medication within the next 6 months.","100 Years",{"count":144,"type":21},120,[24],"Severe skeletal wasting and catabolic weight loss are highly common among patients with heart failure with reduced ejection fraction (HFrEF). This prospective randomized controlled trial will compare changes in the muscle mass in the arms and the legs (appendicular lean mass) in patients with HFrEF randomized between 3 groups of no, low- or high-dose protein supplementation. The dietary protein supplementation will be Ensure(R) products manufactured by Abbott Nutrition. The Investigators hypothesize that skeletal muscle wasting in HFrEF is promoted by neurohumoral activation of catabolic metabolism (such as GDF-15 and ActRII pathways) and can be at least partially reversed by increased dietary protein intake. It is anticipated that this study will determine whether dietary protein supplementation helps to prevent muscle wasting and will advance understanding of the GDF-15 and ActRII muscle wasting pathways.",[148,29],"Heart Failure","2025-11-24",{"date":151,"type":47},"2025-11-25",{"date":153,"type":47},"2023-04-24",{"date":155,"type":21},"2027-12-31",{"name":157,"class":54},"Tufts Medical Center",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":166,"sex":17,"minAge":167,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":105},"100455547","phase-1-safety-and-tolerability-of-imm01-stem-in-patients-with-muscle-atrophy-related-to-knee-osteoarthritis-100455547","NCT05211986","Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis.","An Open-label Dose Escalation Study to Assess the Safety and Tolerability of IMM01-STEM in Participants With Muscle Atrophy Related to Knee Osteoarthritis","STEM-MYO","Inclusion Criteria:\n\n* Has moderate KOA (defined as Kellgren-Lawrence \\[KL\\] grade 2 to 3) on affected limb\n* Has quadriceps weakness (\\\u003C7.5N\u002Fkg)\n* Can ambulate \\>50 feet unassisted\n* This criteria deleted with protocol amendment 6\n* Has a body mass index (BMI) of \\\u003C40kg\u002Fm2\n* A male must agree to use contraception during the treatment period and for at least 3 months after the last dose of study treatment and refrain from donating sperm during this period.\n* A female is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n  1. Not a woman of childbearing potential (WOCBP). OR\n  2. A WOCBP who agrees to follow the protocol's contraceptive guidance during the treatment period and for at least 3 months after the last dose of study treatment.\n* Female has a negative pregnancy test result at screening and prior to investigational medicinal product (IMP) administration\n* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol\n* Willing and able to comply with all study requirements, according to the judgment of the Investigator\n* Has discontinued systemic oral or intravenous steroid use for 6 months prior to Screening\n* Has vital sign measurements within the following ranges at Baseline (predose at Visit 2): heart rate \\>50 and \\\u003C100 bpm, systolic blood pressure \\>100 and \\\u003C170 mmHg, diastolic blood pressure \\>50 and \\\u003C90 mmHg, and blood oxygenation (by pulse-oximetry) \\>95%\n* Participant has undergone and failed at least 1 3-month or longer treatment regimen (ie, activity modification, weight loss, physical therapy, anti-inflammatory medications, or injection therapy) within a 2-year period prior to the Screening visit.\n* Study participant is able to speak, read, and understand English, in order to understand the nature of this study.\n\nExclusion Criteria:\n\n* Severe KOA (defined as KL grade \\>3) on contralateral limb\n* Has had prior total knee arthroplasty\n* Has a known hypersensitivity to any components of the study medication or comparative drugs (and\u002For an investigational device) as stated in this protocol\n* Has current or past history of malignancy (5y) excluding nonmelanoma skin cancer\n* Has neurological, vascular, or cardiac condition that limit function, or, in the opinion of the investigator, could jeopardize or would compromise the study participant's ability to participate in this study\n* Has uncontrolled comorbidities including diabetes (hemoglobin A1c level \\>7.0%), Hypertension (resting heart rate \\>100 bpm, systolic blood pressure \\>170 mmHg, or diastolic blood pressure \\>90 mmHg), cardiovascular disease, asthma, or COPD.\n* Is known positive for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCVAb) or human immunodeficiency virus-1\u002F2 antibody (HIV-1\u002F2Ab). Patients with a negative RNA test for HCV are acceptable.\n* Is taking a prohibited medication or has taken a prohibited medication (narcotic pain medication, local anti-inflammatory, other investigational drugs)\n* Participant has had a change in medication to manage comorbid condition(s) (including diabestes, hypertension, asthma, and cardiovascular disease) within 1 month of the Screening visit.\n* Participant received intra-articular cortisone or viscosupplementation product(eg, Synvisc®) injections within 3 months prior to the first dose of IMP.\n* Has had administration of a live, attenuated vaccine within 28 days of starting study treatment or anticipation that such vaccine will be required during the study Prior\u002Fconcurrent clinical study experience\n* Has current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)\n* This criteria was deleted with protocol amendment 6\n* This criteria was deleted with protocol amendment 6\n* This criteria was deleted with protocol amendment 6\n* Has current or past history (10y) of smoking\n* Has a history of chronic alcohol or drug abuse within the previous 3 months\n* Participant is currently using a systemic oral or intravenous steroid regimen (eg, for asthma or other chronic respiratory condition) or brief course of systemic pulse steroid administration (eg, for flare up of nonarthritic condition or COVID-19).",true,"50 Years","75 Years",{"count":170,"type":21},28,[172,91],"PHASE1","An open-label dose escalation study to assess the safety and tolerability of IMM01-STEM in participants with muscle atrophy related to knee osteoarthritis",[29],"2025-10-28",{"date":177,"type":47},"2025-10-30",{"date":179,"type":47},"2022-09-13",{"date":181,"type":21},"2026-06-30",{"name":183,"class":184},"Immunis, Inc.","INDUSTRY",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":166,"sex":17,"minAge":192,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":22,"phases":196,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":55},"100564582","fit-exercise-in-30d-of-ulls-induced-muscle-disuse-100564582","NCT06631053","FIT Exercise in 30d of ULLS-induced Muscle Disuse","Use of Velocity Monitoring to Prescribe Appropriate Flywheel-based Inertial Training (FIT) Workloads for Exercise in Space Flight","Inclusion Criteria:\n\n* Regularly engaging in aerobic exercise (\\> 150min\u002Fwk) and resistance exercise (\\>1 time per week) for the past 12 months\n* Education greater than or equal to bachelor's degree (any field)\n\nExclusion Criteria:\n\n* Waist circumference \\\u003C 55cm or \\> 90cm (F) and \\\u003C 75cm or \\> 100cm (M)\n* Body mass index \\\u003C 18.5 or \\> 29.9\n* Shoe size \\\u003C 25 or \\>29cm.\n* Not regularly engaging in exercise for previous 12 months\n* Tobacco use within previous 6 months\n* Blood clotting disorder\n* Heart arrhythmia\n* Implanted device which could negatively be affected by electrical impulse or strong magnetic field such as pacemaker, internal defibrillator, or cochlear implant\n* Diagnosed cardiovascular, pulmonary, renal, or metabolic disease\n* Pregnancy (within previous 6 months)\n* Oral contraceptive use (within previous three months)\n* High resting blood pressure (\\>140 systolic and\u002For \\> 90 diastolic)\n* Currently or previously undergone gender-affirming therapy (hormone therapy or sexual reassignment surgery)\n* Low back or leg injury in previous 6 months\n* Currently taking medication to assist with sleep\n* Muscle, bone, or joint injury that limits physical activity within previous 6 months\n* Neurological disorder which affects balance (such as multiple sclerosis or Parkinson's disease)","35 Years","45 Years",{"count":195,"type":21},16,[24],"This study aims to determine how flywheel-based inertial training (FIT) implemented according to principles of velocity-based training (VBT) and High-Intensity Interval Training (HIIT) affects disuse-induced physical de-conditioning including loss of voluntary muscle strength, aerobic capacity, and balance regulation.",[29,199],"Muscle Weakness",[201,202,203,204],"spaceflight","unweighting","disuse","exercise","2025-10-22",{"date":207,"type":47},"2025-10-24",{"date":209,"type":47},"2024-10-23",{"date":211,"type":21},"2026-09-01",{"name":213,"class":54},"Lance Bollinger",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":221,"minAge":87,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":224,"phases":4,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":230,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":237,"locationsCount":4},"100603278","identifying-fundamental-mechanisms-of-skeletal-muscle-ageing-in-older-men-undergoing-androgen-deprivation-therapy-a-feasibility-study-100603278","NCT07134439","Identifying Fundamental Mechanisms of Skeletal Muscle Ageing in Older Men Undergoing Androgen Deprivation Therapy: a Feasibility Study","MASS-ADT","Inclusion Criteria:\n\n* Age ≥65 years old at time of recruitment\n* Able to provide informed consent to participate\n* Known prostate cancer due to be initiated on ADT for the first time (with or without Androgen Receptor Targeted Agents (ARTA) or radiotherapy), or initiated within two weeks prior to recruitment.\n* Individuals involved in other research will be eligible to participate so long as the other research does not involve potential changes to the standard ADT care the participant will be receiving and does not involve an intervention aimed at reducing the muscle atrophy associated with ADT.\n\nExclusion Criteria:\n\n* Systemic anti-cancer therapy within one year of recruitment (for prostate cancer or any other concomitant cancer)\n* Planned surgery (not including eye surgery or other minor surgery) within six months of ADT\n* Any other condition previous or current which, in the judgement of the responsible clinician, is likely to interfere with the trial \u002F assessments.\n* Lacks capacity to consent\n\nExclusion criteria for those consenting to optional muscle biopsy:\n\n* On treatment with clopidogrel, high-dose aspirin, dipyridamole or anticoagulants\n* Known bleeding disorder or platelets \\\u003C75x103\u002FmL","MALE",{"count":223,"type":21},20,"OBSERVATIONAL","To find out whether it is possible to run a study looking at the underlying markers of ageing in muscle quality and quantity in men receiving Androgen Deprivation Therapy for prostate cancer treatment.\n\nTo determine the feasibility of conducting an observational study examining the association of fundamental biological markers of ageing with changes in body composition and skeletal muscle morphology following ADT in older men undergoing prostate cancer treatment.",[227,228,29,229],"Sarcopenia","Prostate Cancer","Androgen Deprivation Therapy","NOT_YET_RECRUITING","2025-08-14",{"date":233,"type":47},"2025-08-21",{"date":235,"type":21},"2025-09",{"date":102,"type":21},{"name":238,"class":54},"Guy's and St Thomas' NHS Foundation Trust",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":249,"conditions":250,"keywords":253,"overallStatus":230,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":55},"100595407","continuous-passive-motion-to-prevent-ankle-contracture-and-muscle-atrophy-in-ventilated-patients-100595407","NCT07032051","Continuous Passive Motion to Prevent Ankle Contracture and Muscle Atrophy in Ventilated Patients","Preventive Effects of Continuous Passive Motion on Ankle Contracture and Muscle Atrophy in Mechanically Ventilated Patients: A Pilot Study","CPM-ICU","Inclusion Criteria:\n\n\\- Eligible participants were adults (≥18 years) with acute respiratory failure expected to require mechanical ventilation for \\>5 days.\n\nExclusion Criteria:\n\n* Neuromuscular disorders\n* Recent lower limb surgery or trauma\n* Critical limb ischemia\n* Limb amputation\n* Deep vein thrombosis\n* Significant leg wounds\n* Pregnancy.",{"count":223,"type":21},[24],"This clinical trial aims to evaluate whether continuous passive motion (CPM) can prevent ankle joint contracture and muscle atrophy in critically ill patients receiving mechanical ventilation in the ICU. The study will also assess the feasibility and safety of implementing CPM therapy in this population.\n\nThe primary objectives are:\n\nTo determine whether CPM preserves ankle dorsiflexion range of motion during ICU immobilization.\n\nTo assess whether ultrasound can detect changes in tibialis anterior muscle morphology in response to CPM.\n\nIn this within-subject design, each participant will receive CPM therapy on one ankle while the contralateral ankle serves as the control. Outcomes related to joint mobility and muscle condition will be compared between the two sides.\n\nParticipants will:\n\nReceive CPM treatment on one ankle for 30 minutes, twice daily, for up to 7 days or until ICU discharge.\n\nUndergo goniometric and ultrasound assessments at baseline and after the intervention.\n\nContinue to receive standard ICU care throughout the study period.",[251,252,29],"Ankle Contracture","Critically Ill Intensive Care Unit Patients",[254,255,256,257],"ICU-acquired weakness","muscle ultrasound","ankle contracture","continuous passive motion,","2025-06-26",{"date":260,"type":47},"2025-06-29",{"date":262,"type":21},"2025-06-25",{"date":264,"type":21},"2025-12-31",{"name":266,"class":54},"Shin Kong Wu Ho-Su Memorial Hospital",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":142,"enrollmentInfo":273,"targetDuration":4,"studyType":224,"phases":4,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":55},"100535536","changes-in-skeletal-muscle-thickness-in-patients-with-acute-heart-failure-100535536","NCT06253104","Changes in Skeletal Muscle Thickness in Patients With Acute Heart Failure","Inclusion Criteria:\n\n1. Over 18 years of age\n2. Ejection fraction \\\u003C40%\n3. Cardiogenic shock defined by clinical criteria (including any of: lactate \\>2.5 mmol\u002FL, systolic blood pressure \\\u003C90 mmHg, acute kidney or liver injury, or cardiac index \\\u003C2.1 on hemodynamic monitoring) plus the clinical requirement for at least one pressor, inotrope, or temporary mechanical circulatory support device (MCSD)\n\nExclusion Criteria:\n\n1. History of LVAD or other durable ventricular assist device\n2. An identified clinical disorder associated with skeletal muscle weakness\u002Fwasting (e.g., muscular dystrophy, mitochondrial disorder, active cancer, modified Rankin score greater or equal to 4 post-stroke\n3. Chronic enteric and parenteral nutrition support patients\n\nIntubation or prior history of heart transplantation are not exclusion criteria if the inclusion criteria are otherwise met.",{"count":89,"type":21},"This study aims to determine, via skeletal muscle ultrasound (US), the extent, timing and relationship between skeletal muscle mass loss and outcomes after orthotropic heart transplantation (OHT) and left ventricular assist device (LVAD) implantation amongst patients with cardiogenic shock. Advanced therapies such as OHT and VADs in the heart failure (HF) population may promote skeletal muscle mass and subsequent quality of life, but there is a lack of literature assessing muscle mass changes in HF patients before and after advanced therapies using US imaging. Therefore this observational study will provide further insight into the 1) changes in lean body mass during critical illness and 2) the feasibility of using bedside US to assess lean body mass in the inpatient setting.",[148,29,276,277],"Skeletal Muscle Atrophy","Cardiogenic Shock","2025-04-18",{"date":280,"type":47},"2025-04-23",{"date":282,"type":47},"2024-02-19",{"date":284,"type":21},"2026-12-31",{"name":157,"class":54},{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":166,"sex":221,"minAge":167,"maxAge":294,"enrollmentInfo":295,"targetDuration":4,"studyType":22,"phases":296,"briefSummary":297,"conditions":298,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":55},"100471086","impacts-of-mechanistic-target-of-rapamycin-mtor-inhibition-on-aged-human-muscle-rapamune-100471086","NCT05414292","Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle (Rapamune)","Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle.","Rapamune","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study\n* Participant is physically able to complete the resistance exercise training programme\n\nExclusion Criteria:\n\n* • A BMI \\\u003C18 or \\>35 kg\u002Fm2\n\n  * Active cardiovascular, cerebrovascular or respiratory disease: e.g. uncontrolled hypertension (BP \\> 160\u002F100), angina, heart failure (class III\u002FIV), arrhythmia, right to left cardiac shunt, recent cardiac event, COPD, pulmonary hypertension or recent stroke\n  * Any metabolic disease\n  * Clotting dysfunction\n  * A history of, or current neurological or musculoskeletal conditions (e.g. epilepsy)\n  * Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance (this must remain for ALL UoN FMHS UREC approved studies)\n  * Contraindications to MRI scanning including claustrophobia, pacemaker, metal implants etc. which will be assessed through an MRI safety screening questionnaire.\n  * Contraindications to the use of Rapamycin e.g. those due scheduled vaccinations (as rapamycin can reduce the efficacy of vaccines).","90 Years",{"count":195,"type":21},[24],"As people age, muscle mass and function is lost and exercise training is an important way to reduce the effects of this and remain independent. However, not everyone can perform this exercise and the muscle responses to exercise are often reduced in older people. So far there has been no drug found to specifically treat or reduce this problem.\n\nMuscle size depends on the balance of muscle protein breakdown and synthesis (building). This balance is regulated by multiple signals within the body, but a particular molecule - the mechanistic target of rapamycin (mTOR), is known to play an important role. For protein synthesis to build up the muscles, this pathway is needed to start the process when triggered by eating protein or exercise. Although this would suggest that mTOR activity is good, excessive levels of this signalling seem to have negative impacts on muscle maintenance with age.\n\nIn animal studies, blocking mTOR signalling has stopped the development of a number of age-related diseases and increased health-span. Drugs that block this pathway (e.g. Rapamune) reduce the stimulation of muscle protein synthesis, possibly through changing the immune system, but conversely have also been shown to increase muscle size and reduce markers of nerve supply loss. This means that drugs which block the mTOR pathway could, in older people, help to reduce the negative impacts of excessive mTOR signalling on muscle size and function.\n\nThe investigators aim to recruit 16 healthy male volunteers over 50 years old to investigate how the drug Rapamune (which blocks the mTOR pathway) affects aged human muscle both on its own and when combined with resistance exercise training.",[29,299],"Age-Related Sarcopenia","2025-04-07",{"date":302,"type":47},"2025-04-10",{"date":304,"type":47},"2021-08-06",{"date":306,"type":21},"2027-05-01",{"name":53,"class":54},{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":11,"sex":17,"minAge":316,"maxAge":317,"enrollmentInfo":318,"targetDuration":4,"studyType":22,"phases":320,"briefSummary":321,"conditions":322,"keywords":325,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":55},"100455153","achilles-tendon-for-the-treatment-of-gluteus-medius-insufficiency-100455153","NCT05206838","Achilles Tendon for the Treatment of Gluteus Medius Insufficiency","Achilles Tendon Homograft for the Treatment of Gluteus Medius Insufficiency After Hip Replacement","HLS","Inclusion Criteria:\n\n* Persisting limping with positive Trendelenburg's sign for at least 12 months after total hip arthroplasty\n* Rupture\u002Favulsion of the gluteus medius tendon verified with ultrasound or MRI\n* Leg length discrepancy of less than 1 cm\n* Femoral offset discrepancy of less than 25%\n\nExclusion Criteria:\n\n* Neuromuscular disorders","40 Years","80 Years",{"count":319,"type":21},44,[24],"Residual limping after total hip arthroplasty is a serious complication that lacks effective treatment. The purpose of this study is to evaluate a surgical treatment for residual limping and compare its results with non-surgical treatment. Our hypothesis is that surgical treatment followed by physiotherapy increases hip function and reduces limping compared with non-surgical treatment with physiotherapy alone.",[323,199,29,324],"Arthroplasty Complications","Muscle Tear",[326,327,328,329],"Gluteus medius","Limp","Abductor","Trendelenburg","2025-04-05",{"date":332,"type":47},"2025-04-08",{"date":334,"type":47},"2022-06-29",{"date":336,"type":21},"2028-12",{"name":338,"class":54},"Sahlgrenska University Hospital",{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":17,"minAge":316,"maxAge":317,"enrollmentInfo":347,"targetDuration":4,"studyType":22,"phases":349,"briefSummary":350,"conditions":351,"keywords":354,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":364,"locationsCount":55},"100455907","the-role-of-surgical-approach-on-residual-limping-after-total-hip-arthroplasty-100455907","NCT05216666","The Role of Surgical Approach on Residual Limping After Total Hip Arthroplasty","Abductor Insufficiency After Total Hip Arthroplasty; Risk Factors and Diagnosis","HSS","Inclusion Criteria:\n\n* Primary unilateral osteoarthritis of the hip scheduled for total hip arthroplasty.\n* Ability to understand and write swedish.\n\nExclusion Criteria:\n\n* Impaired funktion of the contralateral hip or knees causing limping.\n* Neuromuscular diseases\n* Postoperative leg length discrepancy excceding 1 cm\n* Postoperative discrepancy in femoral offset exceeding 25% of the femoral offset of the contralateral hip.",{"count":348,"type":21},580,[24],"Residual limping after total hip arthroplasty is empirically associated with the use of lateral approach but has been reported in litterature even with the use of posterior approach. The purpose of this clinical trial is to compare the risk of residual limping one year after total hip arthropasty between lateral and posterior approach.",[352,199,29,353,323],"Hip Osteoarthritis","Muscle Injury",[355,356,357,329,358],"abductor","approach","limp","gluteus medius",{"date":360,"type":47},"2025-04-09",{"date":362,"type":47},"2022-05-11",{"date":336,"type":21},{"name":338,"class":54},{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":166,"sex":17,"minAge":372,"maxAge":317,"enrollmentInfo":373,"targetDuration":4,"studyType":22,"phases":375,"briefSummary":376,"conditions":377,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":55},"100344190","the-role-of-type-2-diabetes-on-skeletal-muscle-atrophy-and-recovery-following-bed-rest-in-older-adults-100344190","NCT03761446","The Role of Type 2 Diabetes on Skeletal Muscle Atrophy and Recovery Following Bed Rest in Older Adults","REST","Inclusion Criteria\n\n1. Participant must be male or female between the ages of 60 and 80 years of age.\n2. Participant has pre-diabetes or type 2 diabetes and is only taking DPP-4 inhibitors, Sulfonylureas and\u002For Metformin therapy (but not Insulin, injectable incretin mimeticsSGL2 inhibitors, and Thiazolidinedione's), and has an A1C \\\u003C 8.0.\n\n   1. Pre-Diabetics are defined as having an HgbA1c of greater than or equal to 5.7% and less 6.5%, or a fasting glucose of greater than or equal to 100 mg\u002Fdl and less than 126 mg\u002Fdl or has a glucose of greater than or equal to 140 mg\u002Fdl and less than 200mg\u002Fdl at the 2 hour blood draw during OGTT\n   2. The non-diabetic control group is defined as having an HgbA1c of less than 5.7%, a fasting glucose of less than 100 mg\u002Fdl and a glucose level less than 140 mg\u002Fdl at the 2hr blood draw during the OGTT.\n3. Participant must have renal function with an estimated glomerular filtration rate (eGFR) \\> 45 ml\u002Fmin\u002F1.73m2 determined at screening.\n4. Participant's triglyceride level is \\\u003C 350 mg\u002Fdl and LDL cholesterol is ≤ 150 mg\u002Fdl at screening.\n5. Participants must be non-smokers. Non-smokers as defined by not smoking any tobacco or using nicotine-containing products and not using vape pens or vaporizers within 3 months prior to screening.\n6. Participant states willingness to follow protocol as described, including consumption of study product per protocol, the prescribed activity level and completing any forms needed throughout the study.\n7. Participant has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board\u002FIndependent Ethics Committee, and provided Health Insurance Portability and Accountability Act authorization (HIPAA) or other privacy authorization prior to any participation in study.\n\nExclusion Criteria\n\n1. Participant has type 1 Diabetes.\n2. BMI \\> 40.0 kg\u002Fm2\n3. Participant is actively pursuing weight loss and\u002For lifestyle changes.\n4. Participant has a history of pressure ulcers.\n5. Participant has a stated history of Deep Vein Thrombosis (DVT), pulmonary embolism, or a known hypercoagulable condition, or other clotting or bleeding disorders.\n6. History of gastrointestinal or intracranial hemorrhage.\n7. History of stroke or cerebrovascular accident.\n8. Recent history of major trauma (within 3 months).\n9. Thrombocytopenia (of any cause) or hyperkalemia (K \\> 5.0) on screening laboratory assay. May repeat lab value per PI discretion.\n10. Untreated or poorly controlled hypertension (SBP \\> 150, DBP \\> 95), or hypotension (SBP \\\u003C100 DBP \\\u003C60)\n11. Participant has a TSH greater than or equal to 10mIU\u002FL.\n12. Participant has current infection (requiring prescription antimicrobial or antiviral medication, or hospitalization), or corticosteroid treatment (with the exception of inhaled or topical steroids) in the last 3 months prior to screening visit.\n13. Participant is currently taking anti-inflammatory medication or has anti-inflammatory medication in the 1 weeks prior to screening (including over the counter formulations; e.g. Aleve, Motrin, ibuprofen, naproxen).\n14. Participant has had surgery requiring \\> 2 days of hospitalization in the last 1 month prior to screening visit.\n15. Participant has an active malignancy or autoimmune disease.\n16. Participant has current significantly impaired liver function in the opinion of the study PI (mild asymptomatic fatty liver is acceptable), or hepatic enzyme tests are ≥ 2.5 times normal limit.\n17. Participant has a chronic, contagious, infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV.\n18. Participant is an amputee and\u002For has presence of partial or full artificial limb.\n19. Participant has had a significant cardiovascular event (e.g. myocardial infarction, stroke) ≤ 6 months prior to screening visit; or stated history of congestive heart failure; or participant has evidence of cardiovascular disease assessed during the ECG at screening. In the event of a positive stress test, participants are referred to their primary care physician. If the electrocardiogram (ECG) is determined to be a false positive, participant may be allowed to participate in study after confirmatory records obtained.\n20. Participant has a history of, or currently has uncontrolled severe diarrhea, nausea or vomiting.\n21. Participant has an obstruction of the gastrointestinal tract, inflammatory bowel disease, short bowel syndrome or other forms of gastrointestinal disease such as stage III or above gastroesophageal reflux disease, gastroparesis, peptic ulcer disease, celiac disease, intestinal dysmotility, diverticulitis, ischemic colitis and bariatric surgery.\n22. Participant cannot abstain from alcohol for the pre bed rest and bed rest portion of the study. For the recovery portion of the study the participant must agree to consume no more than 1 glass of wine (4-5 oz) or bottle of beer (12 oz) \u002Fday.\n23. Participant cannot refrain from taking medications\u002Fdietary supplements\u002Fherbals or substances that could modulate glucose metabolism (other than oral hypoglycemic medications), or are considered anabolic, or reduce weight (fat mass), or that may interact with low-molecular weight heparin or induce hypo- or hyper-coagulable state, in the opinion of the PI or medical provider, starting one week prior to enrollment and over the entire course of the study. These include progestational agents (except prescribed birth control), steroids, growth hormone, dronabinol, marijuana, calcium-beta-hydroxy-betamethylbutyrate (CaHMB), free amino acid supplements and dietary supplements to aid weight loss.\n24. Participant has a mini-Mental State Examination score \\\u003C 21.\n25. Subjects who fulfill any of the contraindications for MRI; examples include metal implants, devices, paramagnetic objects contained within the body and excessive or metal-containing tattoos.\n26. Unable to participate in MR or DEXA assessments due to physical limitations of equipment tolerances (e.g., MRI bore size and DEXA 450-pound weight limit) claustrophobia, or based on Investigator's judgment at screening.\n27. Participant has a sensitivity or allergy to lidocaine.\n28. Participant has a sensitivity or allergy to heparin, enoxaparin, or other low molecular weight heparin.\n29. History of allergy to pork products or any component of the formulation of low-molecular weight heparin for dosing.\n30. History of heparin induced thrombocytopenia.\n31. Hemoglobin \\\u003C 10.0 g\u002FdL for females; \\\u003C 11.0 g\u002FdL for males; or participant has clinically significant signs\u002Fsymptoms of anemia in the opinion of the PI or medical provider.\n32. Concomitant medications with known contraindication or interaction with low-molecular weight heparin (including anti-platelet agents, anti-coagulant agents, non-steroidal anti-inflammatory drugs)\n33. Presence of any condition that, in the opinion of the Investigator, compromises participant safety or data integrity or the participant's ability to complete the study.\n34. Participant experiences symptoms of claudication. Symptoms include cramping pain in the legs and\u002For difficulty walking.","60 Years",{"count":374,"type":21},50,[24],"The goal of this study is to determine the impact of pre-diabetes and type 2 diabetes on muscle atrophy during a period of bed rest and recovery of muscle mass, strength, and physical function following bed rest.",[378,29,379,380,381],"Type 2 Diabetes","Aging","Sedentary Behavior","Pre-diabetes","2025-03-12",{"date":384,"type":47},"2025-03-13",{"date":386,"type":47},"2019-03-18",{"date":388,"type":21},"2025-12",{"name":390,"class":54},"AdventHealth Translational Research Institute",{"id":392,"slug":393,"hasResults":11,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":397,"eligibilityCriteria":398,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":168,"enrollmentInfo":399,"targetDuration":4,"studyType":22,"phases":401,"briefSummary":402,"conditions":403,"keywords":407,"overallStatus":230,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":4},"100562278","achilles-tendon-rupture---intervention-with-electrical-stimulation-100562278","NCT06601088","Achilles Tendon Rupture - Intervention With Electrical Stimulation","Acute Achilles Tendon Rupture - Intervention With Neuromuscular Electrical Stimulation","C-NMES-ATR","Inclusion Criteria:\n\n* Diagnosed with acute unilateral Achilles tendon rupture\n* Included within 10 days after injury.\n\nExclusion Criteria:\n\n* Inability to give consent to participate,\n* ongoing treatment with anticoagulants,\n* known allergy to contrast agents,\n* planned follow-up at another hospital,\n* inability to follow instructions,\n* known renal failure,\n* heart failure with pitting edema,\n* thrombophlebitis,\n* thromboembolic disease within the last 3 months,\n* previous surgery of the tendon,\n* known malignancy,\n* hemophilia,\n* pregnancy,\n* treatment with high doses of acetylsalicylic acid.",{"count":400,"type":21},220,[24],"Acute Achilles tendon rupture (ATR) is an injury that is commonly associated with complications, such as blood clotting, muscle loss and tendon lengthening, all of which affect the long-term outcome and return to sports. These complication are related to the treatment of ATR with lower leg immobilization in a boot.\n\nThe investigators aim to demonstrate that an intervention with calf neuromuscular electrical stimulation (C-NMES) during leg immobilization after ATR can 1) reduce blood clots, 2) lower the degree of muscle loss, 3) decrease tendon lengthening and 4) improve long-term outcome.",[404,405,406,29],"Achilles Tendon Ruptures","Immobilization","Venous Thromboembolism (VTE)",[33,408],"duplex ultrasound","2024-09-15",{"date":411,"type":47},"2024-09-19",{"date":413,"type":21},"2025-01-15",{"date":415,"type":21},"2026-12-30",{"name":417,"class":54},"Karolinska University Hospital"]